Skip to content
Arphio logo — Rare but not alone

Arphio

Rare but not alone

Founded 2022 Malta Malta 4 employees Health Care, Pharmaceutical

General Information

Company Name Arphio
Founded Year 2022
Location Malta Malta
Employees 4
Industries Health Care, Pharmaceutical
Social

BounceWatch is an independent company data service, not affiliated with Arphio. To contact Arphio, visit arphio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Arphio compare?

A PDF of Arphio and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Arphio soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Arphio

Arphio is an orphan pharmaceutical company with the slogan "Rare but not alone." The company is dedicated to enhancing patient access to crucial treatments for rare diseases by partnering with industry experts to identify therapeutics either in development or available in select countries and make them accessible globally. Founded in 2022 by pharmaceutical professionals with extensive expertise, Arphio focuses on rare disease detection, market access, and the international supply of orphan drugs. Headquartered in Malta, the company is powered by DrugsIntel (DI), a data science powerhouse that processes pharmaceutical data from over 75 countries and 6,000 sources to ensure the successful launch of orphan drugs in the market. Arphio aims to address the lengthy diagnostic process for orphan conditions, estimated to take around seven years and visits to 10 different doctors, by leveraging its intelligence tools and partnerships.

Business keywords: Rare diseases, Orphan pharmaceuticals, Patient access, Drug development, Global market access, Pharmaceutical professionals, Data science, Pharmaceutical data, Market intelligence, Therapeutics, Orphan drug supply, Healthcare industry, Diagnostic expertise

No funding data available for Arphio yet.

Arphio Alternatives & Competitors

View All Alternatives
Arphio vs

Focused on the research and development of therapeutics for infectious diseases and rare disorders

Post-IPO Equity
5 employees
Health Care, Pharmaceutical
Arphio vs
Komtur
Komtur Germany

Komtur delivers comprehensive healthcare solutions that connect pharmaceutical innovations with pati...

153 employees
Health Care, Pharmaceutical
Arphio vs
Aceragen
Aceragen United States

Aceragen is a rare disease company striving to restore a better life for patients and families.

Private Equity
2 employees
Biotechnology, Health Care

FAQ About Arphio

Rare but not alone
Arphio was founded in 2022.
Arphio is headquartered in Malta.
Arphio operates in Health Care and Pharmaceutical. Its work centres on Rare diseases, Orphan pharmaceuticals, Patient access and Drug development.
Arphio has approximately 4 employees.
Top alternatives and competitors to Arphio include Revive Therapeutics Ltd. CSE: RVV | USA: RVVTF, Komtur, Aceragen, Versantis, Dynacure. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Arphio and Revive Therapeutics Ltd. CSE: RVV | USA: RVVTF are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Arphio, https://bouncewatch.com/company/arphio, updated 11 May 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout